Study on Atebimetinib and Modified Chemotherapy for First-Line Treatment of Metastatic Pancreatic Cancer
Sponsor: Immuneering Corporation
ClinicalTrials ID:NCT07562152
This clinical trial is testing whether a new drug combination, atebimetinib with modified chemotherapy, can improve survival in patients with metastatic pancreatic cancer compared to the standard chemotherapy treatment.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The aim of this study is to find out if adding a new drug, atebimetinib, to a modified schedule of chemotherapy drugs gemcitabine and nab-paclitaxel can help patients with metastatic pancreatic cancer live longer than using the standard chemotherapy alone. Patients will be randomly assigned to receive either the new combination treatment or the standard chemotherapy as their first treatment for this type of cancer.
Description
This international study is in Phase 3, which means it is testing the effectiveness and safety of a new treatment on a larger group of patients. The study is open-label, so both the doctors and patients know which treatment is being given. Participants will be divided into two groups: one group will receive atebimetinib along with a modified schedule of the chemotherapy drugs gemcitabine and nab-paclitaxel, while the other group will receive the standard schedule of gemcitabine and nab-paclitaxel. The goal is to see if the new combination can help patients with metastatic pancreatic cancer live longer than the standard treatment.
Eligibility Criteria
Inclusion Criteria
- Must be 18 years or older.
- Must have a confirmed diagnosis of metastatic pancreatic cancer for at least 12 weeks before joining the study.
- Must be in good overall health, with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
- Must not have received any previous treatment for pancreatic cancer.
- Must have at least one measurable tumor that can be tracked using standard criteria.
- Must have adequate organ function and meet specific laboratory test requirements.
Exclusion Criteria
- Cannot swallow pills.
- Have a different type of pancreatic cancer, such as squamous, adenosquamous, neuroendocrine, or acinar carcinoma.
- Have only locally advanced pancreatic cancer, not metastatic.
- Have untreated or worsening cancer that has spread to the brain or central nervous system.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| City of Hope | 85338 | Phoenix | Arizona |
| City of Hope | 91010 | Duarte | California |
| Piedmont Healthcare | 30318 | Atlanta | Georgia |
| City of Hope | 60099 | Chicago | Illinois |
| Missouri Cancer Associates | 65201 | Columbia | Missouri |
| Comprehensive Cancer Centers | 89169 | Las Vegas | Nevada |
| Regional Cancer Care | 07109 | Belleville | New Jersey |
| NYU Langone Health | 10016 | New York | New York |
| Taylor Cancer Research Center | 43537 | Maumee | Ohio |
| Sarah Cannon Research Institute | 37203 | Nashville | Tennessee |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.